Matthew Gline - 24 Feb 2025 Form 3 Insider Report for Arbutus Biopharma Corp (ABUS)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: ABUS
Reported as of: 24 Feb 2025
Net transaction value: $0
SEC form: 3
Accepted by SEC: 06 Mar 2025, 16:07:01 UTC
Prior SEC filing: 24 Feb 2025
Next SEC filing: 24 Mar 2025
Source filing: View source filing
Reporting owner signature: /s/ David C. Hastings as attorney-in-fact for Matthew Gline

Key filing fact

Matthew Gline filed Form 3 for Arbutus Biopharma Corp (ABUS) on 06 Mar 2025.

Key facts

This page summarizes Matthew Gline's Form 3 filing for Arbutus Biopharma Corp (ABUS).
0 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 06 Mar 2025, 16:07.

Change

Previous filing in this sequence was filed on 24 Feb 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABUS holding

Common Shares

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 38,847,462
Date: 24 Feb 2025
Ownership: By Roivant Sciences Ltd.
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Reporting Person is the Principal Executive Officer and a director of Roivant Sciences Ltd. (''Roivant'') and may be deemed to have beneficial ownership of the securities of the Issuer held by Roivant. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

SEC remarks

Exhibit 24: Power of Attorney